Drug Profile

Pitavastatin - Zydus Pharmaceuticals

Alternative Names: Pitava; Pitavastatin magnesium; Zypitamag

Latest Information Update: 19 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Zydus Pharmaceuticals (USA)
Class Alcohols; Alkenes; Antihyperlipidaemics; Carboxylic acids; Cyclopropanes; Fluorobenzenes; Quinolines; Skin disorder therapies; Small molecules
Mechanism of Action HMG-CoA reductase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Dyslipidaemias; Hyperlipidaemia

Most Recent Events

30 Sep 2019 Medicure acquires ownership of pitavastatin from Zydus for USA and Canadian markets
01 May 2018 Launched for Dyslipidaemias in USA (PO)
01 May 2018 Launched for Hyperlipidaemia in USA (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com